Application of interleukin-38 in the preparation of products for preventing and treating obesity and metabolic syndrome

Abstract

The invention discloses an application of interleukin-38 in preparing products for preventing and treating obesity and metabolic syndrome. Furthermore, the metabolic syndrome is diabetes and fatty liver; the dosage of interleukin-38 is 2.5 microgram DNA / g weight, and the effective using form is pcDNA3.1-1L-38-His plasmid; the plasmid is structured by using KpnI and XbaI double digest pc DNA 3.1 (+) and interleukin-38 PCR product, and the recombinant plasmid formed by linking enzyme-digested products of the both is pcDNA3.1-1L-38-His plasmid. The interleukin-38 can effectively delay the fat happening and developing progresses, effectively inhibit the mice weight increase, reduce the cell hypertrophy of adipose tissue, effectively regulate the mice adjusting ability to sugar, inhibit the expression of inflammatory cells, and reduce the generation of the liver triglyceride; the application provides a high-efficient, toxic-free and safe new concept for the prevention and treatment of obesity and metabolic syndrome, and has wide application prospect.

Description

technical field [0001] The invention belongs to the field of biotechnology, and specifically relates to the application of interleukin-38 in the preparation of products for preventing and treating obesity and metabolic syndrome. Background technique [0002] Obesity refers to the phenomenon of excessive accumulation and / or abnormal distribution of fat in the body and weight gain. It is a chronic metabolic disease caused by the interaction of genetic factors, environmental factors and other factors. With the development of economy and the change of lifestyle, obesity has become a global problem. Obesity not only affects the beauty of the body, but also brings inconvenience to life. The most important thing is that it is easy to cause complications, such as type II diabetes, fatty liver, hypertension, hyperlipidemia, and various tumor diseases, accelerating aging and death. Metabolic syndrome refers to the pathological state of metabolic disorders of proteins, fats, carbohydr...

AI Technical Summary

Problems solved by technology

[0004] At present, the mechanism of action of drugs used clinically to treat obesity can be divided into three categories: (1) lipase inhibition mechanism: orlistat is a potent, selective, long-acting, reversible gastrointestinal Lipase inhibitors can slow down the hydrolysis process of food fat in the gastrointestinal tract, thereby reducing the hydrolysis and absorption of fat in the diet by 25% to 30%, but it is easy to cause discomfort in the gastrointestinal tract

(2) Mechanism of appetite suppression: Liraglutide acts on the feeding center of the hypothalamus, which can increase the satiety signal of the hypothalamus, reduce the hunger signal of the hypothalamus, reduce appetite, and then reduce calorie intake, but it is prone to nausea, stomach Adverse reactions such as intestinal reactions

Existing drugs for the treatment of obesity will cause varying degrees of damage to the body

Images